Last reviewed · How we verify
Acquired hypothyroidism - replacement therapy — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Levoxyl | Levothyroxine Sodium | Pfizer Inc. | Thyroid hormone replacement | Thyroid receptor proteins attached to DNA |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Acquired hypothyroidism - replacement therapy
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Acquired hypothyroidism - replacement therapy:
- Acquired hypothyroidism - replacement therapy treatment updates — RSS
- Acquired hypothyroidism - replacement therapy treatment updates — Atom
- Acquired hypothyroidism - replacement therapy treatment updates — JSON
Cite this brief
Drug Landscape (2026). Acquired hypothyroidism - replacement therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acquired-hypothyroidism-replacement-therapy. Accessed 2026-06-10.
Related
- Acquired hypothyroidism - replacement therapy full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing